Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Overview

This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).

Full Title of Study: “A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: April 2009

Interventions

  • Drug: E5555
  • Drug: Placebo

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
  • Active Comparator: 2
    • Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
  • Active Comparator: 3
    • Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
  • Placebo Comparator: 4
    • Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability
    • Time Frame: Up to 16 weeks

Secondary Measures

  • Incidence of Major Adverse Cardiovascular Events; Platelet Aggregation Inhibition; Holter Monitoring. Exploratory Outcome Measure: effects on endovascular inflammatory processes
    • Time Frame: Up to 16 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Males or Females, 45 – 80 years of age 2. Presenting with features of non-ST segment elevation ACS (unstable angina or Myocardial infarction without persistent ST elevation). and at least one of the following two criteria on admission: Cardiac enzymes≥ ULN for the local institution OR ECG changes compatible with ischemia 3. Randomisation possible within 24 hours of the onset of the most recent symptomatic episode. EXCLUSION CRITERIA:

1. History of acquired or congenital bleeding disorder, coagulopathy or platelet disorder, or history of pathological bleeding within the last 6 months 2. History of intracranial bleeding, history of hemorrhagic retinopathy, history of recent ischemic stroke or transient ischemic attack, or known structural cerebral vascular lesion 3. Recent trauma, major surgery, Percutaneous coronary intervention or coronary artery surgery 4. Clinically significant haematological, hepatic or renal abnormalities 5. Patients with some specific ST-segment changes, severe congestive heart failure or uncontrolled cardiac arrhythmias at baseline 6. Recent significant (as determined by the investigator) cardiovascular events

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Eisai Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rafal Ziecina, MD, Study Director, Eisai Limited

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.